<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hydrochlorothiazide: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hydrochlorothiazide: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Hydrochlorothiazide: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="8529" href="/d/html/8529.html" rel="external">see "Hydrochlorothiazide: Drug information"</a> and <a class="drug drug_patient" data-topicid="11757" href="/d/html/11757.html" rel="external">see "Hydrochlorothiazide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52867128"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Hydro [DSC];</li>
<li>APO-Hydrochlorothiazide;</li>
<li>MINT-Hydrochlorothiazide;</li>
<li>PMS-Hydrochlorothiazide;</li>
<li>TEVA-Hydrochlorothiazide</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1059275"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihypertensive Agent</span>;</li>
<li>
<span class="list-set-name">Diuretic, Thiazide</span></li></ul></div>
<div class="block don drugH1Div" id="F53462470"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Bronchopulmonary dysplasia (BPD):</b> Limited data available; efficacy results variable. <b>Note:</b> Although the benefits of diuretic therapy in management of BPD are variable (eg, optimal duration of therapy, impact on pulmonary endpoints), diuretics continue to be used in clinical practice (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23478874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23478874'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: 1 to 2 mg/kg/<b>dose</b> every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2677293','lexi-content-ref-Eichenwald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2677293','lexi-content-ref-Eichenwald.1'])">Ref</a></span>); used most often in preterm neonates at PNA &gt;28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23478874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23478874'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes insipidus, central:</b> Very limited data available: Oral: 2 to 3 mg/kg/day in 2 divided doses, used most often in combination with a low-solute diet. Dosing based on a retrospective chart review of newborns treated with hydrochlorothiazide and low-solute feeds (n=4); no episodes of hyponatremia or hypernatremia were reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25002871']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25002871'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Edema (diuresis), hypertension:</b> Limited data available: Oral: 1 to 2 mg/kg/<b>dose</b> every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Eichenwald.1','lexi-content-ref-Fanaroff.1','lexi-content-ref-16898855']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Eichenwald.1','lexi-content-ref-Fanaroff.1','lexi-content-ref-16898855'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment in renal impairment:</b> There are no neonatal-specific recommendations; per manufacturer labeling (adult), use is contraindicated in patients with anuria:</p>
<p style="text-indent:-2em;margin-left:4em;">Hydrochlorothiazide is excreted by the kidney; use with caution; consider dosage adjustments (eg, 50% to 100% of normal dose) for moderate renal impairment; avoid use in severe renal impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16898855']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16898855'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F179625"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4ddb56d1-0e77-423d-981b-3c407d3f8eea">Bronchopulmonary dysplasia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bronchopulmonary dysplasia (BPD):</b> Limited data available; efficacy results variable. <b>Note:</b> Although the benefits of diuretic therapy in management of BPD are variable (eg, optimal duration of therapy, impact on pulmonary endpoints), diuretics continue to be used in clinical practice (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23478874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23478874'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: Oral: 3 to 4 mg/kg/day in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2677293','lexi-content-ref-2926575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2677293','lexi-content-ref-2926575'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0abb4c4d-97b2-469f-9d23-5b67a088f30b">Diabetes insipidus, central</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes insipidus, central:</b> Very limited data available: Infants and Children &lt;3 years: Oral: 1 to 2 mg/kg/day. Dosing based on retrospective descriptive analysis (n=13, age range: 0.5 to 27 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26130110']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26130110'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6b3bf4fb-d61c-4d60-acaa-a34bb1a9f68a">Edema</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Edema (diuresis)</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16898855','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16898855','lexi-content-ref-Manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &lt;6 months: Oral: 1 to 2 mg/kg/day in 1 to 2 divided doses; some infants may require 3 mg/kg/day in 2 divided doses; maximum daily dose: 37.5 mg/<b>day.</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children &lt;2 years: Oral: 1 to 2 mg/kg/day in 1 to 2 divided doses; maximum daily dose: 37.5 mg/<b>day.</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years: Oral: 1 to 2 mg/kg/day in 1 to 2 divided doses; maximum daily dose: 100 mg/<b>day.</b></p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Limited data available: Oral: 1 to 2 mg/kg/day in 1 to 2 divided doses. <b>Note:</b> Maximum adult daily dose recommended for heart failure-related edema: 200 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants &lt;6 months: Oral: 1 to 2 mg/kg/day in 1 to 2 divided doses; some infants may require 3 mg/kg/day in 2 divided doses; maximum daily dose: 37.5 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29192011','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29192011','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children &lt;2 years: Oral: 1 to 2 mg/kg/day in 1 to 2 divided doses; maximum daily dose: 37.5 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29192011','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29192011','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years: Oral: 1 to 2 mg/kg/day in 1 to 2 divided doses; maximum daily dose: 100 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>); a lower maximum dose of 37.5 mg/day has been suggested by recent guidelines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29192011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29192011'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Limited data available: Oral: Initial: 1 mg/kg/day once daily; may increase to maximum daily dose: 3 mg/kg/<b>day</b> or 50 mg/<b>day</b>, whichever is lower (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15286277','lexi-content-ref-NIH.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15286277','lexi-content-ref-NIH.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ef2a577e-45af-4cd2-b217-d6ab39845170">Hypercalciuria</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypercalciuria:</b> Limited data available: Infants, Children, and Adolescents: Oral: Initial: 1 to 2 mg/kg/day in 1 to 2 divided doses; lower initial doses of 0.5 mg/kg/day has been reported in infants and children; titrate until goal urinary calcium excretion goals reached and symptoms resolve; treatment usually continued for 1 year; usual adult dose: 25 to 100 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21284722','lexi-content-ref-22857835','lexi-content-ref-21525575','lexi-content-ref-9793728']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21284722','lexi-content-ref-22857835','lexi-content-ref-21525575','lexi-content-ref-9793728'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1f6c2a04-c752-45f2-882f-d80001bcab3f">Nephrogenic diabetes insipidus, congenital</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nephrogenic diabetes insipidus, congenital:</b> Limited data available: Infants, Children, and Adolescents: Oral: Usual dosage range: 1 to 3 mg/kg/day in combination with amiloride. Dosing based on a retrospective descriptive analysis (n=30, age range: 1 month to 40 years), and a retrospective analysis (n=10, median age at diagnosis: 1.6 years [age range: 0.16 to 6.33 years]), and a pediatric case series (n=4) in patients receiving hydrochlorothiazide in combination with amiloride (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24337364','lexi-content-ref-10332005','lexi-content-ref-10477148']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24337364','lexi-content-ref-10332005','lexi-content-ref-10477148'])">Ref</a></span>). In adults, usual dose is 25 mg once or twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Irwin.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Irwin.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51113041"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b>Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">GFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Use not recommended; use is contraindicated with anuria.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent:</b> Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-334435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-334435'])">Ref</a></span>); there are no dosage adjustments provided in the manufacturer's labeling; use not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> There are no dosage adjustments provided in the manufacturer's labeling; use not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51113042"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, use with caution and monitor for precipitation of hepatic coma.</p></div>
<div class="block doa drugH1Div" id="F179604"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8529" href="/d/html/8529.html" rel="external">see "Hydrochlorothiazide: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="03194794-c12b-455b-a783-1c51d4ea319f">Calcium nephrolithiasis, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Calcium nephrolithiasis, prevention (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 25 mg once daily; titrate based on tolerance and urinary calcium levels to usual effective dose of 50 to 100 mg/day in 1 to 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26800461','lexi-content-ref-24857648','lexi-content-ref-Curhan.1','lexi-content-ref-10916098','lexi-content-ref-6375276','lexi-content-ref-7176047']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26800461','lexi-content-ref-24857648','lexi-content-ref-Curhan.1','lexi-content-ref-10916098','lexi-content-ref-6375276','lexi-content-ref-7176047'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ccc9bbd1-ebdb-45a6-88d5-f40653130227">Diabetes insipidus, nephrogenic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes insipidus, nephrogenic (off-label use)</b>:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consider for use in addition to a low-solute diet to help reduce polyuria (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Irwin.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Irwin.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 25 mg once or twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Irwin.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Irwin.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="65ef282d-23a6-4668-9e37-3d9d9236ddb8">Edema or general volume overload</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Edema or general volume overload (adjunctive to loop diuretic): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>
<b>:</b> Optimize loop diuretic therapy before adding hydrochlorothiazide; combination diuretic therapy is typically for short-term use to restore euvolemia in patients already taking high-dose loop diuretic therapy who are resistant (eg, furosemide total daily dose of 160 to 320 mg/day IV or the oral equivalent). Combination diuretic therapy can cause severe electrolyte depletion (eg, potassium, magnesium, sodium); prior to and during therapy, electrolytes should be monitored and appropriately managed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31526538','lexi-content-ref-35363499','lexi-content-ref-Brater.1','lexi-content-ref-21029871']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31526538','lexi-content-ref-35363499','lexi-content-ref-Brater.1','lexi-content-ref-21029871'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 25 to 50 mg once or twice daily; may increase dose as needed based on response and tolerability up to a maximum of 200 mg/day; may be administered in combination with or shortly before the scheduled loop diuretic. Assess volume status frequently (eg, daily or at least every 2 to 3 days) to determine effectiveness and avoid over-diuresis. Continue until euvolemia is restored, although some patients may require maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-Brater.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-Brater.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f0c92d9-ad08-4643-a848-3296ddf5258e">Hypertension, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>When a thiazide diuretic is chosen, chlorthalidone or indapamide is preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-Mann.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-Mann.1'])">Ref</a></span>). For patients who warrant combination therapy (blood pressure ≥20/10 mm Hg above goal or suboptimal response to initial monotherapy), may use in combination with another appropriate agent (eg, angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, dihydropyridine calcium channel blocker) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>). However, some experts prefer regimens that do not include thiazide diuretics for combination therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mann.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mann.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 12.5 to 25 mg once daily; evaluate response after ~2 to 4 weeks and titrate dose, as needed, up to 50 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-Mann.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-Mann.1'])">Ref</a></span>); some experts do not recommend doses higher than 25 mg/day because of greater adverse effects without additional antihypertensive effect; if additional blood pressure control is needed, consider combination therapy. Patients with severe asymptomatic hypertension and no signs of acute end organ damage should be evaluated for medication titration within 1 week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19052124','lexi-content-ref-Mann.1','lexi-content-ref-30883050']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19052124','lexi-content-ref-Mann.1','lexi-content-ref-30883050'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991076"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥10 mL/minute: No dosage adjustment necessary. The diuretic effect is diminished with CrCl &lt;30 mL/minute, but small, short-term studies suggest hypertensive benefit may be preserved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22951101','lexi-content-ref-15615808','lexi-content-ref-22235821','lexi-content-ref-25018961','lexi-content-ref-8583780','lexi-content-ref-30905361','lexi-content-ref-26987648']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22951101','lexi-content-ref-15615808','lexi-content-ref-22235821','lexi-content-ref-25018961','lexi-content-ref-8583780','lexi-content-ref-30905361','lexi-content-ref-26987648'])">Ref</a></span>). Switching to a loop diuretic may be considered if BP is no longer controlled or if management of fluid overload is required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25018961']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25018961'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;10 mL/minute: Use not recommended due to lack of efficacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30425103','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30425103','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-334435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-334435'])">Ref</a></span>); use not recommended due to lack of efficacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-334435','lexi-content-ref-30425103']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-334435','lexi-content-ref-30425103'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Use not recommended due to lack of efficacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30425103']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30425103'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> In general, use not recommended; fluid management can be more effectively managed using CRRT ultrafiltration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT </b>
<b>(eg, sustained, low-efficiency diafiltration):</b> In general, use not recommended; fluid management can be more effectively managed using PIRRT ultrafiltration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988354"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, use with caution and monitor for precipitation of hepatic coma.</p></div>
<div class="block arsc drugH1Div" id="F54997481"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Dermatologic toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b> Skin photosensitivity</b> may occur with hydrochlorothiazide. Cumulative use may increase the risk for <b>squamous cell carcinoma </b>(SCC)<b> of skin </b>(lip) and <b>basal cell carcinoma</b> (BCC) <b>of skin</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22869299','lexi-content-ref-29217346','lexi-content-ref-28480532']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22869299','lexi-content-ref-29217346','lexi-content-ref-28480532'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Skin photosensitivity: Non-dose-related; idiosyncratic. Diuretics reduce the minimum UV radiation needed to produce a sunburn-like response, increasing the risk of phototoxicity and potentially photocarcinogenesis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24812037']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24812037'])">Ref</a></span>). SCC and BCC: Dose- and time-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29217346','lexi-content-ref-28480532']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29217346','lexi-content-ref-28480532'])">Ref</a></span>); risk may be mediated through skin photosensitivity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22869299','lexi-content-ref-29217346','lexi-content-ref-28480532']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22869299','lexi-content-ref-29217346','lexi-content-ref-28480532'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>SCC/BCC: Delayed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22869299','lexi-content-ref-29217346','lexi-content-ref-28480532']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22869299','lexi-content-ref-29217346','lexi-content-ref-28480532'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">SCC/BCC:</p>
<p style="text-indent:-2em;margin-left:8em;">• Cumulative use (ie, ≥5 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22869299','lexi-content-ref-29217346','lexi-content-ref-28480532']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22869299','lexi-content-ref-29217346','lexi-content-ref-28480532'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Electrolyte disturbances</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Reversible <b>hypokalemia</b>, <b>hypomagnesemia</b>, <b>hypercalcemia</b>, and <b>hyponatremia </b>may occur with hydrochlorothiazide and may increase the risk of arrhythmias. Development of electrolyte disturbances may be minimized when used in combination with other electrolyte-sparing antihypertensives (eg, angiotensin-converting enzyme, angiotensin receptor blockers, or aldosterone inhibitors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21896142']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21896142'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; related to the pharmacologic action. Thiazide diuretics block the NaCl cotransporter in the distal convoluted tubule, leading to decreased reabsorption of sodium and chloride and increased delivery of sodium to the collecting duct, which leads to increased potassium wasting. Diluting capacity of the kidney is also impaired, leading to decreased magnesium and increased calcium concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24243991']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24243991'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; hypokalemia generally occurs within 2 weeks of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22099511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22099511'])">Ref</a></span>). Hyponatremia onset may range from 2 weeks to 10 years after treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22017784']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22017784'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• High doses (&gt;25 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22099511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22099511'])">Ref</a></span>) or concurrent loop diuretic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21896142']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21896142'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypokalemia: GI losses (eg, vomiting, diarrhea) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22783025']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22783025'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypomagnesemia: Heart failure, poor magnesium intake, high alcohol intake (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10653441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10653441'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hyponatremia: Increased water intake (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22783025']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22783025'])">Ref</a></span>); older patients, females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24811554']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24811554'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypercalcemia: Older patients, females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17904464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17904464'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Gout</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hydrochlorothiazide may cause <b>hyperuricemia</b> and precipitate gout or gouty arthritis in susceptible individuals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21896142']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21896142'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose- and time-related; related to the pharmacologic action. Diuretics increase reabsorption of uric acid in the proximal tubule, reducing urinary excretion, increasing the risk of hyperuricemia and gout (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22240117']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22240117'])">Ref</a></span>). Volume contraction with use of diuretics may also contribute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24449584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24449584'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Rapid; hyperuricemia and gout generally occur within the first few days of treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22240117','lexi-content-ref-22099511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22240117','lexi-content-ref-22099511'])">Ref</a></span>) but may occur up to one year after treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22783025']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22783025'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• High doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22240117']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22240117'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Increased duration of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31641556']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31641556'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Personal or family history of gout (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22099511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22099511'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypersensitivity reactions (immediate and delayed): </b>Hypersensitivity reactions, both immediate and delayed, have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17296538']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17296538'])">Ref</a></span>). Delayed hypersensitivity reactions range from maculopapular skin rash to rare severe cutaneous adverse reactions, including <b>acute generalized exanthematous pustulosis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29409745','lexi-content-ref-11558881','lexi-content-ref-30755424']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29409745','lexi-content-ref-11558881','lexi-content-ref-30755424'])">Ref</a></span>). Other hypersensitivity reactions include <b>interstitial nephritis</b> and <b>interstitial pneumonitis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2049694','lexi-content-ref-7446559']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2049694','lexi-content-ref-7446559'])">Ref</a></span>). Additionally, hydrochlorothiazide has rarely been associated with <b>noncardiogenic pulmonary edema</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27613469','lexi-content-ref-17536614','lexi-content-ref-16164399','lexi-content-ref-19249954','lexi-content-ref-30756041','lexi-content-ref-32139213']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27613469','lexi-content-ref-17536614','lexi-content-ref-16164399','lexi-content-ref-19249954','lexi-content-ref-30756041','lexi-content-ref-32139213'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Immediate hypersensitivity reactions: Non-dose-related; immunologic (ie, IgE-mediated, with specific antibodies formed against a drug allergen following initial exposure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30275849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30275849'])">Ref</a></span>). Delayed hypersensitivity reactions: Non-dose-related; immunologic (ie, involving a T-cell mediated drug-specific immune response) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549'])">Ref</a></span>). Noncardiogenic pulmonary edema: Unknown; various proposed mechanisms including immunologic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10084412']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10084412'])">Ref</a></span>), idiosyncratic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30756041','lexi-content-ref-16433212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30756041','lexi-content-ref-16433212'])">Ref</a></span>), and mast cell or complement activation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32139213']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32139213'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Immediate hypersensitivity reactions: Rapid; generally occur within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-NICE.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-NICE.2014'])">Ref</a></span>). Delayed hypersensitivity reactions: Varied; typically occur days to 6 weeks after drug exposure, but may occur more rapidly (usually within 1 to 4 days) upon reexposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-NICE.2014','lexi-content-ref-11558881']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-NICE.2014','lexi-content-ref-11558881'])">Ref</a></span>). Noncardiogenic pulmonary edema: Rapid; occurs within 10 to 150 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16164399']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16164399'])">Ref</a></span>); upon rechallenge, symptoms develop more rapidly and are often severe (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30756041']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30756041'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity: Limited published information regarding possible cross-reactivity between hydrochlorothiazide and other sulfonamides (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20108448','lexi-content-ref-17296538','lexi-content-ref-1984112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20108448','lexi-content-ref-17296538','lexi-content-ref-1984112'])">Ref</a></span>). Cross-reactivity due to antibody production (anaphylaxis) is unlikely to occur with nonantibiotic sulfonamides and antibiotic sulfonamides (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31495421']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31495421'])">Ref</a></span>). Cross-reactivity among thiazide diuretics is unknown.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ocular Effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Sulfa derivatives, such as hydrochlorothiazide, may rarely cause acute transient <b>myopia</b> and <b>acute angle-closure glaucoma</b> which is generally reversible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25477363','lexi-content-ref-21655050']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25477363','lexi-content-ref-21655050'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non-dose-related; idiosyncratic (ie, suggested to involve ciliochoroidal effusion and anterior rotation of the ciliary body, leading to myopic shift and angle closure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21655050']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21655050'])">Ref</a></span>). Hyponatremia may also play a role (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25477363']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25477363'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; reported to occur between 2 days and 7 years after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25477363','lexi-content-ref-7575249','lexi-content-ref-21655050']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25477363','lexi-content-ref-7575249','lexi-content-ref-21655050'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F179563"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions are dose-related, with the majority occurring with doses ≥25 mg.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypersensitivity angiitis, hypotension (including orthostatic)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, skin rash, toxic epidermal necrolysis, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Glycosuria, hypomagnesemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps, anorexia, constipation, diarrhea, gastric irritation, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Aplastic anemia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, headache, paresthesia, restlessness, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia, muscle spasm</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (transient), xanthopsia</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Reap 2019), psoriasis (Song 2021), skin photosensitivity (Rosenthal 2019), Stevens-Johnson syndrome (Assad 1978)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercalcemia (rare: &lt;1%) (Desai 2010; Wermers 2007), hyperglycemia (Zhang 2016), hyperuricemia (more frequent: ≥4% to &lt;10%) (McAdams DeMarco 2012; Palmer 2011), hypochloremic alkalosis (Pela 2008), hypokalemia (Schell 2019), hyponatremia (common: ≥10%) (Leung 2011; Sardar 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Pancreatitis (Spera 2016), sialadenitis (Thomopoulos 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Impotence (Handler 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Chrein 1962), basal cell carcinoma of skin (more frequent: ≥4% to &lt;10%) (Pedersen 2018), hemolytic anemia (Shirey 1988), leukopenia (Sosenko 2019), malignant neoplasm of lip (Friedman 2012), purpuric disease (Okafor 1986), squamous cell carcinoma of skin (common: ≥10%) (Pottegård 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic hepatitis (Taglietti 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (Ruscin 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Systemic lupus erythematosus (Sosenko 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Acute angle-closure glaucoma (rare: &lt;1%) (Chen 2014), myopia (rare: &lt;1%) (Roh 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Interstitial nephritis (Magil 1980)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pneumonitis (Biron 1991), noncardiogenic pulmonary edema (Goetschlalckx 2007)</p></div>
<div class="block coi drugH1Div" id="F179578"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to hydrochlorothiazide, any component of the formulation, or sulfonamide-derived drugs; anuria</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Although the FDA-approved product labeling states this medication is contraindicated in patients with hypersensitivity to sulfonamide-containing drugs, the scientific basis of this cross-sensitivity has been challenged. See “Warnings/Precautions” for more detail.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Increasing azotemia and oliguria during treatment of severe progressive renal disease; breast-feeding</p></div>
<div class="block war drugH1Div" id="F179560"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfonamide (“sulfa”) allergy: The FDA-approved product labeling for many medications containing a sulfonamide chemical group includes a broad contraindication in patients with a prior allergic reaction to sulfonamides. There is a potential for cross-reactivity between members of a specific class (eg, two antibiotic sulfonamides). However, concerns for cross-reactivity have previously extended to all compounds containing the sulfonamide structure (SO<sub>2</sub>NH<sub>2</sub>). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides. T-cell-mediated (type IV) reactions (eg, maculopapular rash) are less well understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (Stevens-Johnson syndrome/TEN), some clinicians choose to avoid exposure to these classes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal insufficiency: Avoid use of diuretics for treatment of elevated blood pressure in patients with primary adrenal insufficiency (Addison disease). Adjustment of glucocorticoid/mineralocorticoid therapy and/or use of other antihypertensive agents is preferred to treat hypertension (Bornstein 2016; Inder 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ascites due to cirrhosis: Use with extreme caution or avoid hydrochlorothiazide in the management of ascites due to cirrhosis; may lead to rapid development of hyponatremia when used in combination with spironolactone and furosemide (AASLD [Runyon 2012]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery: Dehydration: Avoid diuretics in the immediate postoperative period after bariatric surgery; electrolyte disturbances and dehydration may occur. Diuretics may be resumed, if indicated, once oral fluid intake goals are met (Ziegler 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with severe hepatic dysfunction; in progressive or severe liver disease, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy/coma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use; should be discontinued prior to testing for parathyroid function.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Cumulative effects may develop, including azotemia, in patients with impaired renal function. Avoid in severe renal disease (ineffective).</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic lupus erythematosus (SLE): May cause SLE exacerbation or activation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical patients: If given the morning of surgery, hydrochlorothiazide may render the patient volume depleted and blood pressure may be labile during general anesthesia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer's labeling.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878484"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F179571"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 12.5 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 12.5 mg, 25 mg, 50 mg</p></div>
<div class="block geq drugH1Div" id="F179556"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F179581"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (hydroCHLOROthiazide Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg (per each): $0.42 - $0.43</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (hydroCHLOROthiazide Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg (per each): $0.17 - $0.82</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.08</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.13 - $0.16</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867129"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 12.5 mg, 25 mg, 50 mg, 100 mg [DSC]</p></div>
<div class="block exp drugH1Div" id="F50770266"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Compounding instructions and stability based on data for compounding hydrochlorothiazide and spironolactone 5 mg/mL oral suspension</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>5 mg/mL Oral Suspension (ASHP Standard Concentration)</b> (ASHP 2017)</p>
<p style="text-indent:-2em;margin-left:2em;">A 5 mg/mL oral suspension may be made with hydrochlorothiazide tablets and one of three different vehicles (cherry syrup; a 1:1 mixture of Ora-Sweet and Ora-Plus; or a 1:1 mixture of Ora-Sweet SF and Ora-Plus). Crush twenty-four 25 mg tablets in a mortar and reduce to a fine powder. Add 25 mL of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label "shake well" and "protect from light." Stable for 60 days (Allen 1996).</p>
<div class="reference">Allen LV Jr, Erickson MA 3rd. Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids. <i>Am J Health Syst Pharm</i>. 1996;53(19):2304-2309.<span class="pubmed-id">8893069</span></div>
</div>
<div class="block admp drugH1Div" id="F52612990"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May administer with or without food; administer early in day to avoid nocturia; if multiple daily dosing, the last dose should not be administered later than 6 PM unless instructed otherwise.</p></div>
<div class="block adm drugH1Div" id="F179575"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer early in day to avoid nocturia. Take the last dose of multiple doses no later than 6 PM unless instructed otherwise.</p></div>
<div class="block sts drugH1Div" id="F22688399"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F). Protect from light and moisture.</p></div>
<div class="block usep drugH1Div" id="F53567198"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Capsules: Management of hypertension alone or in combination with other antihypertensive agents (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Treatment of edema due to heart failure, hepatic cirrhosis, estrogen, or corticosteroid therapy; treatment of edema associated with various forms of renal dysfunction, including nephrotic syndrome, acute glomerulonephritis, and chronic renal failure; management of hypertension either alone or in combination with other antihypertensive agents (All indications: FDA approved in infants, children, and adults); has also been used for bronchopulmonary dysplasia (BPD), central diabetes insipidus, idiopathic hypercalcuria, and congenital nephrogenic diabetes insipidus.</p></div>
<div class="block mst drugH1Div" id="F179654"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">HCTZ is an error-prone abbreviation (mistaken as hydrocortisone)</p>
<p style="text-indent:-2em;margin-left:4em;">HydroCHLOROthiazide may be confused with hydrALAZINE, hydrocortisone, hydroxychloroquine, hydrOXYzine, Viskazide</p>
<p style="text-indent:-2em;margin-left:4em;">Microzide may be confused with Maxzide, Micronase</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Esidrex [multiple international markets] may be confused with Lasix brand name for furosemide [US, Canada, and multiple international markets]</p>
<p style="text-indent:-2em;margin-left:4em;">Esidrix [Germany] may be confused with Lasix brand name for furosemide [US, Canada, and multiple international markets]</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Diuretics are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299455"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F179565"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Allopurinol: Thiazide and Thiazide-Like Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Thiazide and Thiazide-Like Diuretics may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Thiazide and Thiazide-Like Diuretics may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May increase the serum concentration of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Thiazide and Thiazide-Like Diuretics may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arsenic Trioxide: Thiazide and Thiazide-Like Diuretics may enhance the hypotensive effect of Arsenic Trioxide. Thiazide and Thiazide-Like Diuretics may enhance the QTc-prolonging effect of Arsenic Trioxide.  Management: When possible, avoid concurrent use of arsenic trioxide with drugs that can cause electrolyte abnormalities, such as the thiazide and thiazide-like diuretics.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta2-Agonists: May enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Thiazide and Thiazide-Like Diuretics. The diuretic response is likewise decreased. Management: Consider separating administraton of bile acid sequestrants and thiazide diuretics by at least 4 hours. Monitor for decreased therapeutic effects of thiazide diuretics if coadministered with a bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: Thiazide and Thiazide-Like Diuretics may increase the serum concentration of Calcium Salts. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of Cardiac Glycosides. Specifically, cardiac glycoside toxicity may be enhanced by the hypokalemic and hypomagnesemic effect of thiazide diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloPHOSphamide: Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of CycloPHOSphamide. Specifically, granulocytopenia may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexketoprofen: May enhance the adverse/toxic effect of Sulfonamides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diacerein: May enhance the therapeutic effect of Diuretics. Specifically, the risk for dehydration or hypokalemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of Diazoxide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: Thiazide and Thiazide-Like Diuretics may enhance the hypokalemic effect of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: HydroCHLOROthiazide may enhance the QTc-prolonging effect of Dofetilide. HydroCHLOROthiazide may increase the serum concentration of Dofetilide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipragliflozin: May enhance the adverse/toxic effect of Thiazide and Thiazide-Like Diuretics. Specifically, the risk for intravascular volume depletion may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Thiazide and Thiazide-Like Diuretics may enhance the arrhythmogenic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Licorice: May enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Thiazide and Thiazide-Like Diuretics may decrease the excretion of Lithium.  Management: Reduce the lithium dose if coadministered with thiazide or thiazide-like diuretics. Monitor serum lithium levels during coadministration with thiazide and thiazide-like diuretics.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of Mecamylamine.  Management: Consider avoiding the use of mecamylamine and thiazide diuretics. If combined, mecamylamine prescribing information suggests reducing the mecamylamine dose by 50% in order to avoid excessive hypotension.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methenamine: Thiazide and Thiazide-Like Diuretics may diminish the therapeutic effect of Methenamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: HydroCHLOROthiazide may enhance the nephrotoxic effect of Methotrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the hypercalcemic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide and Thiazide-Like Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): Thiazide and Thiazide-Like Diuretics may increase the serum concentration of Multivitamins/Minerals (with AE, No Iron). Specifically, thiazide diuretics may decrease the excretion of calcium, and continued concomitant use can also result in metabolic alkalosis. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): Thiazide and Thiazide-Like Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: Thiazide and Thiazide-Like Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May diminish the therapeutic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: May enhance the adverse/toxic effect of Diuretics. Opioid Agonists may diminish the therapeutic effect of Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Diuretics may enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: Thiazide and Thiazide-Like Diuretics may enhance the QTc-prolonging effect of Promazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reboxetine: May enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hyponatremic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Thiazide and Thiazide-Like Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide and Thiazide-Like Diuretics may increase the serum concentration of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: Thiazide and Thiazide-Like Diuretics may enhance the hypercalcemic effect of Toremifene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D Analogs: Thiazide and Thiazide-Like Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F58530496"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">When diuretics are used for the treatment of heart failure in patients planning to become pregnant, adjust dose prior to conception to minimize risk of placental hypoperfusion (AHA/ACC/HFSA [Heidenreich 2022]).</p>
<p style="text-indent:0em;margin-top:2em;">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be continued in patients trying to conceive. Hydrochlorothiazide is a second-line agent for the treatment of hypertension in pregnant patients (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019; SOGC [Magee 2022]).</p></div>
<div class="block pri drugH1Div" id="F179582"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Hydrochlorothiazide crosses the placenta (Beerman 1980).</p>
<p style="text-indent:0em;margin-top:2em;">Maternal use may cause fetal or neonatal jaundice, thrombocytopenia, or other adverse events observed in adults.</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke and myocardial infarction (ACOG 2019). Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). Hydrochlorothiazide is a second-line agent for the treatment of hypertension in pregnant patients (ACOG 2019; SOGC [Magee 2022]).</p>
<p style="text-indent:0em;margin-top:2em;">Use of thiazide diuretics during pregnancy may be considered to treat edema due to pathologic causes (as in the nonpregnant patient); monitor.</p>
<p style="text-indent:0em;margin-top:2em;">Heart failure in pregnancy is associated with adverse maternal and fetal outcomes, including premature birth, infants born small-for-gestational-age, increased risk of maternal and fetal death (Bright 2021). Thiazide diuretics may be used for symptom management in pregnant patients with heart failure complicated by pulmonary congestion; closely monitor volume status and adjust dose to minimize risk of placental hypoperfusion (AHA/ACC/HFSA [Heidenreich 2022]; ESC [Regitz-Zagrosek 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">A case report describes the use of hydrochlorothiazide for the treatment of nephrogenic diabetes insipidus during pregnancy (Gala-Błądzińska 2018).</p></div>
<div class="block mopp drugH1Div" id="F53567174"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum electrolytes, BUN, creatinine, blood pressure, fluid balance, body weight, urinary electrolytes (if applicable); serum glucose levels</p></div>
<div class="block pha drugH1Div" id="F179559"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water as well as potassium and hydrogen ions</p></div>
<div class="block phk drugH1Div" id="F179577"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Diuresis: Infants: 2 to 6 hours (Chemtob 1989); Adults: ~2 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: ~4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Infants: 8 hours (Chemtob 1989); Adults: 6 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed; absorption is reduced in patients with CHF.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: 3.6 to 7.8 L/kg (correlates with dose administered and concentration achieved).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~40% to 68%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Not metabolized.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 65% to 75%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~6 to 15 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~1 to 5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (≥61% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F51196165"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Hydrochlorothiazide plasma concentration is increased and the half-life is prolonged.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F179583"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Dichlotride | Esidrex | Monozide</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Diural | Diurex | Diuriten | HCT 25 | Klortiazida | Tandiur</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Hct Lannacher</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Dithiazide</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Acuren | Htz</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Dehydratin Neo | Dehydrazid | Hypodehydra</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Clorana | Clorizin | Diureclor | Diurepina | Diuretic | Diuretil | Diurezin | Diurix | Drenol | Farmanguinhos hidroclorotiazida | Furp hidroclorotiazida | Hidrazim | Hidrobio | Hidroclorana | Hidroclorotiazida | Hidrofall | Hidroflux | Hidrogen | Hidrol | Hidrolan | Hidroless | Hidromed | Hidrotiazida | Iquego hidroclorotiazida | Lafepe hidroclorotiazida | Lfm hidroclorotiazida | Lqfex hidroclorotiazida | Mictrin | Neo hidroclor</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Esidrex</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Apo hydro</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Hidroclorotiazida | Hidroronol</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Hydrochlorothiazid</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Diclotride | Diurizir | Hidroclorotiazida | Hidroclorotiazida mk | Hydrug | Hydruretic | Lonpra</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Hydrochlorothiazid | Hydrochlorothiazid tainex | Hydrochlorothiazide aurovitas</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Diu-melusin | Esidrex | Esidrix | Hct Aaa | Hct Actavis | Hct aiwa | Hct AL | Hct basf | Hct beta | Hct biochemie | Hct CT | Hct Dexcel | HCT Dura | Hct gamma | Hct hexal | Hct Intermuti | Hct Isis | Hct puren | Hct ratiopharm | HCT Sandoz | Hct Stada | HCT Teva | Hctad | Hydrochlorothiazid Dexcel | Hydrochlorothiazide 1a pharma</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">H pres | Hiclor | Hidro Pres | Hidrocard | Hidroclorotiazida | Hidroclorotiazida feltrex | Hidroclorotiazida lam | Hidroclorotiazide | Hidrotiadol | Hypress | Olina | Tiaretic</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">HCT 25 | Hidroclorotiazida</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Hypothiazid</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Hct georetic | Hydretic | Hydrex | Hydrozide</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Drine | Esidrex | Hidroclorotiazid Kern Pharma | Hidroclorotiazida apotex | Hidroclorotiazida aristo | Hidroclorotiazida aurovitas | Hidroclorotiazida kern pharma | Hidroclorotiazida Stada | Hidroclorotiazida vir | Hidrosaluretil | Hydrochlorothiazide sandoz</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Dichlotride | Hct-sal | Hyclosid | Hydresis | Hydrex | Hydrex semi</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Esidrex | Hydrochlorothiazide arrow</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Direma | Hydrosaluric</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Diuren | Esidrex | Hydrochlorothiazid</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo hydrochlorothiazide | Dichlotride | Hydrochlorothiazid | Hydrozide</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Hypothiazid</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Hct | Hydrochlorothiazid</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Hydrosaluric</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Disothiazide | Esidrex</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aquazide | Clothy | Hydrazide | Hydride | Hydronol | Hyzide | Klorzide | Xenia</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Diuzid | Hydrazidawa | Urozide</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Aquazid</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Esidrex | Idroclorotiazide Aurobindo</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Esidrex | Modrex | Monozide</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Dichlotride | Maschitt | Maschitt showa | Newtolide | Pantemon</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Hymet | Hyzide</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dichlodide | Dichlozid | Ildong hydrochlorothiazide</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Esidrex</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Esidrex</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Apo hydro | Dehydratin Neo | Hypothiazide</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Dichlotride | Esidrix</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Dehydratin Neo | Disalunil | Hypothiazide</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Esidrex</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Acortiz | Bidrociral | Diclotride | Diziver | Hidroclorotiazida | Naxtrol | Rofucal | Systocal | Top k | Waser</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo hydro | Hydrochlorzide | Hydrorazide | Hydrozide</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Emzor hydrochlorothiazide | Esinil | Exus hydrochlorothiazide | Hydrex | Redrex</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Hydrochloorthiazide | Hydrochloorthiazide A | Hydrochloorthiazide Alpharma | Hydrochloorthiazide Apotex | Hydrochloorthiazide ratiopharm | Hydrochloorthiazide Sandoz | Hydrochloroth</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Esidrex | Hydrochlorothiazide orion | Hydromed</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Acuren | Diclotride | Diurace | Hidroclorotia | Hidroclorotiaz | Hidroclorotiazida | Tiazid | Zinoxid</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Altiazide | Dichlotride | Diucare | Diuzid | Diuzide | Hydrax | Hytaz | Pharex hydrochlorothiazide | Urilzid</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Diuza | Urozide</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Disalunil | Hydrochlorothiazid | Hydrochlorothiazide aurovitas | Hydrochlorothiazide orion | Hypothiazide</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Esidrix | Hydrochlorothiazid | Hydrodiuril | Microzide | Oretic</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Hidroclorotiazida | Hidrosaluteril</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">As farmil | Clorfal | Daretic | Diurex | Hidramil | Hidroclorotiazida heisecke | Hidroclorotiazida polimed | Hidroclorotiazida vivele | Micciol | Rifor</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Esidrex | HCT Hexal</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Dichlothiazid | Hydrochlorothiazid | Hydrochlorothiazide sar | Hypothiazide</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo hydro | Apo hydrochlorothiazide | Esidrex | Monozide | Pms hydrochlorothiazide</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Esidrex | Hydrochlorothiazide bluefish | Hydrochlorothiazide orifarm | Hydrochlorothiazide orion | Hydroklortiazid ebb | Hydroklortiazid evolan</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo hydro | Di-Ertride | Didralin | Hichlozide | Hydrochlorzide | Hydrozide</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Hydrochlorothiazid | Hydrochlorothiazid leciva</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Apo hydro | Cozide | Didralin | Diuret-p | Hctz | Hychlortide | Hychlorzide | Hydozid | Hydril | Hydrochlorothiazid | Hydromed | Hydrozide | Med-hyazide | Thiazide | Urazide</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Esidrex</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Esidrex</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Colonraitai | Depress | Dichlortride | Dichlotride | Dicomtride | Dihydrodiazid | Dithiazide | Hybozide | Hychlotozide | Hychlozide | Hydrochlorothiazid | Hydrochorothiazide | Koliside | Lisuzone | Nisidrex | Uresan</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Hydrochlorothiazid | Hydrothiazide | Hypothiazide | Tiurex</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Di Tiaziden | Diclorazida | Ditiazid | Diurotiazida | Esidrex | Hidroclorotiazida | Hidrotiazida | Modiur | Moduron | Tiaziden</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Di-Eudrin | Diclotride | Hidroclorotiazida | Hytide</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Gulf hydrochlorothiazide | Hexazide | Ridaq | Urirex</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Hexazide | Hydrex 50</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Staplex | Varidrex</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25002871">
<a name="25002871"></a>Abraham MB, Rao S, Price G, Choong CS. Efficacy of hydrochlorothiazide and low renal solute feed in neonatal central diabetes insipidus with transition to oral desmopressin in early infancy. <i>Int J Pediatr Endocrinol</i>. 2014;2014(1):11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/25002871/pubmed" id="25002871" target="_blank">25002871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22951101">
<a name="22951101"></a>Agarwal R, Sinha AD. Thiazide diuretics in advanced chronic kidney disease. <i>J Am Soc Hypertens</i>. 2012;6(5):299-308. doi:10.1016/j.jash.2012.07.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/22951101/pubmed" id="22951101" target="_blank">22951101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2677293">
<a name="2677293"></a>Albersheim SG, Solimano AJ, Sharma AK, et al. Randomized, Double-Blind, Controlled Trial of Long-Term Diuretic Therapy for Bronchopulmonary Dysplasia. <i>J Pediatr</i>. 1989;115(4):615-620.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/2677293/pubmed" id="2677293" target="_blank">2677293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26130110">
<a name="26130110"></a>Al Nofal A, Lteif A. Thiazide diuretics in the management of young children with central diabetes insipidus. <i>J Pediatr</i>. 2015;167(3):658-661.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/26130110/pubmed" id="26130110" target="_blank">26130110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 203: Chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50. doi:10.1097/AOG.0000000000003020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20108448">
<a name="20108448"></a>Aouam K, Ali HB, Youssef M, et al. Lichenoid eruption associated with hydrochlorothiazide and possible cross reactivity to furosemide. <i>Therapie</i>. 2009;64(5):344-347. doi:10.2515/therapie/2009050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/20108448/pubmed" id="20108448" target="_blank">20108448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007:43.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26800461">
<a name="26800461"></a>Arrabal-Martín M, González-Torres S, Cano-García MD, et al. Urine calcium and bone mineral density in calcium stone-forming patients treated with alendronate and hydrochlorothiazide.<i> Urol Int.</i> 2016;97(3):292-298. doi:10.1159/000443484<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/26800461/pubmed" id="26800461" target="_blank">26800461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-757383">
<a name="757383"></a>Assaad D, From L, Ricciatti D, Shapero H. Toxic epidermal necrolysis in Stevens--Johnson syndrome. <i>Can Med Assoc J</i>. 1978;118(2):154-156.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/757383/pubmed" id="757383" target="_blank">757383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27338866">
<a name="27338866"></a>Bauersachs J, Arrigo M, Hilfiker-Kleiner D, et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>Eur J Heart Fail</i>. 2016;18(9):1096-1105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/27338866/pubmed" id="27338866" target="_blank">27338866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7390276">
<a name="7390276"></a>Beermann B, Fåhraeus L, Groschinsky-Grind M, Lindström B. Placental transfer of hydrochlorothiazide. <i>Gynecol Obstet Invest</i>. 1980;11(1):45-48.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/7390276/pubmed" id="7390276" target="_blank">7390276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-334435">
<a name="334435"></a>Bennett WM, McDonald WJ, Kuehnel E, Hartnett MN, Porter GA. Do diuretics have antihypertensive properties independent of natriuresis? <i>Clin Pharmacol Ther</i>. 1977;22(5, pt 1):499-504.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/334435/pubmed" id="334435" target="_blank">334435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10084412">
<a name="10084412"></a>Bernal C, Patarca R. Hydrochlorothiazide-induced pulmonary edema and associated immunologic changes. <i>Ann Pharmacother</i>. 1999;33(2):172-174. doi:10.1345/aph.18191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/10084412/pubmed" id="10084412" target="_blank">10084412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2049694">
<a name="2049694"></a>Biron P, Dessureault J, Napke E. Acute allergic interstitial pneumonitis induced by hydrochlorothiazide. <i>CMAJ</i>. 1991;145(1):28-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/2049694/pubmed" id="2049694" target="_blank">2049694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26760044">
<a name="26760044"></a>Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(2):364-389. doi:10.1210/jc.2015-1710<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/26760044/pubmed" id="26760044" target="_blank">26760044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15303450">
<a name="15303450"></a>Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. <i>Pharmacotherapy</i>. 2004;24(7):856-870.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/15303450/pubmed" id="15303450" target="_blank">15303450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22099505">
<a name="22099505"></a>Brater DC. Update in diuretic therapy: clinical pharmacology. <i>Semin Nephrol.</i> 2011;31(6):483-494. doi:10.1016/j.semnephrol.2011.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/22099505/pubmed" id="22099505" target="_blank">22099505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brater.1">
<a name="Brater.1"></a>Brater DC, Ellison DH. Causes and treatment of refractory edema in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 26, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34259013">
<a name="34259013"></a>Bright RA, Lima FV, Avila C, Butler J, Stergiopoulos K. Maternal heart failure. <i>J Am Heart Assoc</i>. 2021;10(14):e021019. doi:10.1161/JAHA.121.021019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/34259013/pubmed" id="34259013" target="_blank">34259013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24449584">
<a name="24449584"></a>Bruderer S, Bodmer M, Jick SS, Meier CR. Use of diuretics and risk of incident gout: a population-based case-control study. <i>Arthritis Rheumatol</i>. 2014;66(1):185-196. doi:10.1002/art.38203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/24449584/pubmed" id="24449584" target="_blank">24449584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24337364">
<a name="24337364"></a>Caletti MG, Balestracci A, Di Pinto D. Pre- and post-treatment urinary tract findings in children with nephrogenic diabetes insipidus. <i>Pediatr Nephrol</i>. 2014;29(3):487-490.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/24337364/pubmed" id="24337364" target="_blank">24337364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29409745">
<a name="29409745"></a>Chaabane A, Fadhel NB, Chadli Z, et al. Association of non-immediate drug hypersensitivity with drug exposure: A case control analysis of spontaneous reports from a Tunisian pharmacovigilance database. <i>Eur J Intern Med</i>. 2018;53:40-44. doi:10.1016/j.ejim.2018.01.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/29409745/pubmed" id="29409745" target="_blank">29409745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2677940">
<a name="2677940"></a>Chemtob S, Kaplan BS, Sherbotie JR, et al. Pharmacology of Diuretics in the Newborn. <i>Pediatr Clin North Am</i>. 1989;36(5):1231-1250.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/2677940/pubmed" id="2677940" target="_blank">2677940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25477363">
<a name="25477363"></a>Chen SH, Karanjia R, Chevrier RL, Marshall DH. Bilateral acute angle closure glaucoma associated with hydrochlorothiazide-induced hyponatraemia. <i>BMJ Case Rep</i>. 2014;2014:bcr2014206690. doi:10.1136/bcr-2014-206690<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/25477363/pubmed" id="25477363" target="_blank">25477363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22240117">
<a name="22240117"></a>Choi HK, Soriano LC, Zhang Y, Rodríguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. <i>BMJ</i>. 2012;344:d8190. doi:10.1136/bmj.d8190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/22240117/pubmed" id="22240117" target="_blank">22240117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21284722">
<a name="21284722"></a>Choi JN, Lee JS, Shin JI. Low-dose thiazide diuretics in children with idiopathic renal hypercalciuria. <i>Acta Paediatr</i>. 2011;100(8):e71-e74. doi:10.1111/j.1651-2227.2011.02191.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/21284722/pubmed" id="21284722" target="_blank">21284722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13879240">
<a name="13879240"></a>Chrein MB, Rubin IL. Agranulocytosis secondary to hydrochlorothiazide therapy. Report of a case. <i>JAMA</i>. 1962;181:54-55. doi:10.1001/jama.1962.03050270056014c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/13879240/pubmed" id="13879240" target="_blank">13879240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7246868">
<a name="7246868"></a>Constandis DD, Schriever HG. Severe lithium-induced diabetes insipidus in a surgical patient treated with hydrochlorothiazide. <i>Am J Surg</i>. 1981;141(6):741-743.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/7246868/pubmed" id="7246868" target="_blank">7246868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22857835">
<a name="22857835"></a>Copelovitch L. Urolithiasis in Children: Medical Approach. <i>Pediatr Clin North Am</i>. 2012;59(4):881-896.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/22857835/pubmed" id="22857835" target="_blank">22857835</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27613469">
<a name="27613469"></a>Corominas M, Andrés-López B, Lleonart R. Severe adverse drug reactions induced by hydrochlorothiazide: A persistent old problem. <i>Ann Allergy Asthma Immunol</i>. 2016;117(3):334-335. doi:10.1016/j.anai.2016.07.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/27613469/pubmed" id="27613469" target="_blank">27613469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Curhan.1">
<a name="Curhan.1"></a>Curhan GC. Kidney stones in adults: Prevention of recurrent kidney stones. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 5, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20068444">
<a name="20068444"></a>Desai HV, Gandhi K, Sharma M, Jennine M, Singh P, Brogan M. Thiazide-induced severe hypercalcemia: a case report and review of literature. <i>Am J Ther</i>. 2010;17(6):e234-e236. doi:10.1097/MJT.0b013e3181c6c21b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/20068444/pubmed" id="20068444" target="_blank">20068444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235821">
<a name="22235821"></a>Dussol B, Moussi-Frances J, Morange S, Somma-Delpero C, Mundler O, Berland Y. A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. <i>J Clin Hypertens (Greenwich)</i>. 2012;14(1):32-37. doi:10.1111/j.1751-7176.2011.00564.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/22235821/pubmed" id="22235821" target="_blank">22235821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15615808">
<a name="15615808"></a>Dussol B, Moussi-Frances J, Morange S, Somma-Delpero C, Mundler O, Berland Y. A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. <i>Nephrol Dial Transplant</i>. 2005;20(2):349-353. doi:10.1093/ndt/gfh650<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/15615808/pubmed" id="15615808" target="_blank">15615808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16695887">
<a name="16695887"></a>Earley LE, Orloff J. The mechanism of antidiuresis associated with the administration of hydrochlorothiazide to patients with vasopressin-resistant diabetes insipidus. <i>J Clin Invest.</i> 1962;41(11):1988-1997. doi:10.1172/JCI104657<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/16695887/pubmed" id="16695887" target="_blank">16695887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eichenwald.1">
<a name="Eichenwald.1"></a>Eichenwald EC, ed. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2926575">
<a name="2926575"></a>Engelhardt B, Blalock WA, DonLevy S, et al. Effect of Spironolactone-Hydrochlorothiazide on Lung Function in Infants With Chronic Bronchopulmonary Dysplasia. <i>J Pediatrics</i>. 1989;114:619-624.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/2926575/pubmed" id="2926575" target="_blank">2926575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fanaroff.1">
<a name="Fanaroff.1"></a>Fanaroff AA, Fanaroff JM, eds. <i>Klaus &amp; Fanaroff's Care of the High-Risk Neonate</i>. 6th ed. Philadelphia, PA: Elsevier Saunders; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29192011">
<a name="29192011"></a>Flynn JT, Kaelber DC, Baker-Smith CM, et al; Subcommittee on Screening and Management of High Blood Pressure in Children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents [published correction appears in <i>Pediatrics</i>. 2017;140(6):e20173035 and <i>Pediatrics</i>. 2018;142(3):e20181739]. <i>Pediatrics</i>. 2017;140(3):e20171904.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/29192011/pubmed" id="29192011" target="_blank">29192011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10916098">
<a name="10916098"></a>Frassetto LA, Nash E, Morris RC Jr, Sebastian A. Comparative effects of potassium chloride and bicarbonate on thiazide-induced reduction in urinary calcium excretion. <i>Kidney Int.</i> 2000;58(2):748-752.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/10916098/pubmed" id="10916098" target="_blank">10916098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22869299">
<a name="22869299"></a>Friedman GD, Asgari MM, Warton EM, Chan J, Habel LA. Antihypertensive drugs and lip cancer in non-Hispanic whites. <i>Arch Intern Med</i>. 2012;172(16):1246-1251. doi:10.1001/archinternmed.2012.2754<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/22869299/pubmed" id="22869299" target="_blank">22869299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi:10.1210/jc.2015-4061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29512817">
<a name="29512817"></a>Gala-Błądzińska A, Mrozek A, Kędzior A, Mazur A, Darmochwał-Kolarz D. Treatment of congenital nephrogenic diabetes insipidus in pregnancy. <i>Ginekol Pol.</i> 2018;89(2):112-113. doi:10.5603/GP.a2018.0019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/29512817/pubmed" id="29512817" target="_blank">29512817</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7575249">
<a name="7575249"></a>Geanon JD, Perkins TW. Bilateral acute angle-closure glaucoma associated with drug sensitivity to hydrochlorothiazide. <i>Arch Ophthalmol</i>. 1995;113(10):1231-1232. doi:10.1001/archopht.1995.01100100019012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/7575249/pubmed" id="7575249" target="_blank">7575249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17536614">
<a name="17536614"></a>Goetschalckx K, Ceuppens J, Van Mieghem W. Hydrochlorothiazide-associated noncardiogenic pulmonary oedema and shock: a case report and review of the literature. <i>Acta Cardiol</i>. 2007;62(2):215-220. doi:10.2143/AC.62.2.2020246<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/17536614/pubmed" id="17536614" target="_blank">17536614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10653441">
<a name="10653441"></a>Greenberg A. Diuretic complications. <i>Am J Med Sci</i>. 2000;319(1):10-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/10653441/pubmed" id="10653441" target="_blank">10653441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9291881">
<a name="9291881"></a>Gurwitz JH, Kalish SC, Bohn RL, et al. Thiazide diuretics and the initiation of anti-gout therapy. <i>J Clin Epidemiol</i>. 1997;50(8):953-959.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/9291881/pubmed" id="9291881" target="_blank">9291881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21649845">
<a name="21649845"></a>Handler J. Managing erectile dysfunction in hypertensive patients. <i>J Clin Hypertens (Greenwich)</i>. 2011;13(6):450-454. doi:10.1111/j.1751-7176.2011.00465.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/21649845/pubmed" id="21649845" target="_blank">21649845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31526538">
<a name="31526538"></a>Hollenberg SM, Warner Stevenson L, Ahmad T, et al. 2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of the American College of Cardiology Solution Set Oversight Committee.<i> J Am Coll Cardiol</i>. 2019;74(15):1966-2011. doi:10.1016/j.jacc.2019.08.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/31526538/pubmed" id="31526538" target="_blank">31526538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Leading.1">
<a name="Leading.1"></a>Hydrochlorothiazide [prescribing information]. Fairfield, NJ: Leading Pharma LLC; October 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sciegen.1">
<a name="Sciegen.1"></a>Hydrochlorothiazide capsules [prescribing information]. Hauppauge, NY: Sciegen Pharmaceuticals Inc; July 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Heritage.1">
<a name="Heritage.1"></a>Hydrochlorothiazide tablet [prescribing information]. East Brunswick, NJ: Heritage Pharmaceuticals Inc; August 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hydrochlorothiazide.2011.05">
<a name="Hydrochlorothiazide.2011.05"></a>Hydrochlorothiazide tablet [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; May 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25138826">
<a name="25138826"></a>Inder WJ, Meyer C, Hunt PJ. Management of hypertension and heart failure in patients with Addison's disease. <i>Clin Endocrinol (Oxf)</i>. 2015;82(6):789-792. doi:10.1111/cen.12592<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/25138826/pubmed" id="25138826" target="_blank">25138826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Irwin.1">
<a name="Irwin.1"></a>Irwin RI, Rippe JM, eds. <i>Irwin and Rippe's Intensive Care Medicine. </i>6th ed.<i></i> Lippincott Williams &amp; Wilkins; 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19052124">
<a name="19052124"></a>Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. <i>N Engl J Med.</i> 2008;359(23):2417-2428. doi:10.1056/NEJMoa0806182<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/19052124/pubmed" id="19052124" target="_blank">19052124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21029871">
<a name="21029871"></a>Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. <i>J Am Coll Cardiol</i>. 2010;56(19):1527-1534. doi:10.1016/j.jacc.2010.06.034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/21029871/pubmed" id="21029871" target="_blank">21029871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15644481">
<a name="15644481"></a>Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? A<i>nn Pharmacother</i>. 2005;39(2):290-301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/15644481/pubmed" id="15644481" target="_blank">15644481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25018961">
<a name="25018961"></a>KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Chapter 2: lifestyle and pharmacological treatments for lowering blood pressure in CKD ND patients. <i>Kidney Int Suppl (2011)</i>. 2012;2(5):347-356. doi: 0.1038/kisup.2012.52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/25018961/pubmed" id="25018961" target="_blank">25018961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33637192">
<a name="33637192"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. <i>Kidney Int.</i> 2021;99(3S):S1-S87. doi:10.1016/j.kint.2020.11.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/33637192/pubmed" id="33637192" target="_blank">33637192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31495421">
<a name="31495421"></a>Khan DA, Knowles SR, Shear NH. Sulfonamide hypersensitivity: fact and fiction. <i>J Allergy Clin Immunol Pract</i>. 2019;7(7):2116-2123. doi:10.1016/j.jaip.2019.05.034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/31495421/pubmed" id="31495421" target="_blank">31495421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10332005">
<a name="10332005"></a>Kirchlechner V, Koller DY, Seidl R, et al. Treatment of Nephrogenic Diabetes Insipidus With Hydrochlorothiazide and Amiloride. <i>Arch Dis Child</i>. 1999;80(6):548-552.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/10332005/pubmed" id="10332005" target="_blank">10332005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8583780">
<a name="8583780"></a>Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. <i>J Cardiovasc Pharmacol</i>. 1995;26(3):394-400. doi:10.1097/00005344-199509000-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/8583780/pubmed" id="8583780" target="_blank">8583780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16164399">
<a name="16164399"></a>Knowles SR, Wong GA, Rahim SA, Binkley K, Phillips EJ, Shear NH. Hydrochlorothiazide-induced noncardiogenic pulmonary edema: an underrecognized yet serious adverse drug reaction. <i>Pharmacotherapy</i>. 2005;25(9):1258-1265. doi:10.1592/phco.2005.25.9.1258<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/16164399/pubmed" id="16164399" target="_blank">16164399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30905361">
<a name="30905361"></a>Kramer HJ, Townsend RR, Griffin K, et al. KDOQI US commentary on the 2017 ACC/AHA hypertension guideline.<i> Am J Kidney Dis</i>. 2019;73(4):437-458. doi: 10.1053/j.ajkd.2019.01.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/30905361/pubmed" id="30905361" target="_blank">30905361</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6375276">
<a name="6375276"></a>Laerum E, Larsen S. Thiazide prophylaxis of urolithiasis. A double-blind study in general practice. <i>Acta Med Scand</i>. 1984;215(4):383-389.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/6375276/pubmed" id="6375276" target="_blank">6375276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22017784">
<a name="22017784"></a>Leung AA, Wright A, Pazo V, Karson A, Bates DW. Risk of thiazide-induced hyponatremia in patients with hypertension. <i>Am J Med</i>. 2011;124(11):1064-1072. doi:10.1016/j.amjmed.2011.06.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/22017784/pubmed" id="22017784" target="_blank">22017784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline No. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management.<i> J Obstet Gynaecol Can.</i> 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7446559">
<a name="7446559"></a>Magil AB, Ballon HS, Cameron EC, Rae A. Acute interstitial nephritis associated with thiazide diuretics. Clinical and pathologic observations in three cases. <i>Am J Med</i>. 1980;69(6):939-943. doi:10.1016/s0002-9343(80)80023-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/7446559/pubmed" id="7446559" target="_blank">7446559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.1">
<a name="Mann.1"></a>Mann JFE, Flack JM. Choice of drug therapy in primary (essential) hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 7, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22031222">
<a name="22031222"></a>McAdams DeMarco MA, Maynard JW, Baer AN, et al. Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study. <i>Arthritis Rheum</i>. 2012;64(1):121-129. doi:10.1002/art.33315<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/22031222/pubmed" id="22031222" target="_blank">22031222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24812037">
<a name="24812037"></a>McDonald E, Freedman DM, Alexander BH, et al. Prescription diuretic use and risk of basal cell carcinoma in the nationwide U.S. radiologic technologists cohort. <i>Cancer Epidemiol Biomarkers Prev</i>. 2014;23(8):1539-1545. doi:10.1158/1055-9965.EPI-14-0251<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/24812037/pubmed" id="24812037" target="_blank">24812037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9121593">
<a name="9121593"></a>Meinardi JR, Donders SH. Nephrogenic diabetes insipidus in a lethargic lithium-treated patient. <i>Neth J Med.</i> 1997;50(3):105-109.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/9121593/pubmed" id="9121593" target="_blank">9121593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Microzide.1">
<a name="Microzide.1"></a>Microzide capsules (hydrochlorothiazide) [prescribing information]. Madison, NJ: Allergan USA, Inc; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Microzide.2">
<a name="Microzide.2"></a>Microzide capsules (hydrochlorothiazide) [prescribing information]. Morristown, NJ: Watson Pharma Inc; February 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7131161">
<a name="7131161"></a>Miller ME, Cohn RD, Burghart PH. Hydrochlorothiazide disposition in a mother and her breast-fed infant. <i>J Pediatr</i>. 1982;101(5):789-791. doi:10.1016/s0022-3476(82)80323-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/7131161/pubmed" id="7131161" target="_blank">7131161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19249954">
<a name="19249954"></a>Mineo MC, Cheng EY. Severe allergic reaction to hydrochlorothiazide mimicking septic shock. <i>Pharmacotherapy</i>. 2009;29(3):357-361. doi:10.1592/phco.29.3.357<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/19249954/pubmed" id="19249954" target="_blank">19249954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21525575">
<a name="21525575"></a>Naseri M, Sadeghi R. Role of high-dose hydrochlorothiazide in idiopathic hypercalciuric urolithiasis of childhood. <i>Iran J Kidney Dis</i>. 2011;5(3):162-168.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/21525575/pubmed" id="21525575" target="_blank">21525575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Clinical Practice Guidelines, 2011. National Institutes of Health. <a href="http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf" target="_blank">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>. Accessed June 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15286277">
<a name="15286277"></a>National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. <i>Pediatrics</i>. 2004;114(2)(suppl):555-576.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/15286277/pubmed" id="15286277" target="_blank">15286277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2014">
<a name="NICE.2014"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: diagnosis and management. Clinical guideline 183. https://www.nice.org.uk/guidance/cg183. Published September 3, 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management. NICE guideline, No. 133. http://www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30883050">
<a name="30883050"></a>Ojji DB, Mayosi B, Francis V, et al; CREOLE Study Investigators. Comparison of dual therapies for lowering blood pressure in black Africans. <i>N Engl J Med.</i> 2019;380(25):2429-2439. doi:10.1056/NEJMoa1901113<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/30883050/pubmed" id="30883050" target="_blank">30883050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3943458">
<a name="3943458"></a>Okafor KC, Griffin C, Ngole PM. Hydrochlorothiazide-induced thrombocytopenic purpura. <i>Drug Intell Clin Pharm</i>. 1986;20(1):60-61. doi:10.1177/106002808602000110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/3943458/pubmed" id="3943458" target="_blank">3943458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22099511">
<a name="22099511"></a>Palmer BF. Metabolic complications associated with use of diuretics. <i>Semin Nephrol</i>. 2011;31(6):542-552. doi:10.1016/j.semnephrol.2011.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/22099511/pubmed" id="22099511" target="_blank">22099511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24857648">
<a name="24857648"></a>Pearle MS, Goldfarb DS, Assimos DG, et al; American Urological Association. Medical management of kidney stones: AUA guideline. <i>J Urol</i>. 2014;192(2):316-324.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/24857648/pubmed" id="24857648" target="_blank">24857648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29217346">
<a name="29217346"></a>Pedersen SA, Gaist D, Schmidt SAJ, Hölmich LR, Friis S, Pottegård A. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. <i>J Am Acad Dermatol</i>. 2018;78(4):673-681.e9. doi:10.1016/j.jaad.2017.11.042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/29217346/pubmed" id="29217346" target="_blank">29217346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18538122">
<a name="18538122"></a>Pela I, Bigozzi M, Bianchi B. Profound hypokalemia and hypochloremic metabolic alkalosis during thiazide therapy in a child with Pendred syndrome. <i>Clin Nephrol</i>. 2008;69(6):450-453. doi:10.5414/cnp69450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/18538122/pubmed" id="18538122" target="_blank">18538122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11558881">
<a name="11558881"></a>Pétavy-Catala C, Martin L, Fontès V, Lorette G, Vaillant L. Hydrochlorothiazide-induced acute generalized exanthematous pustulosis. <i>Acta Derm Venereol</i>. 2001;81(3):209. doi:10.1080/000155501750376348<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/11558881/pubmed" id="11558881" target="_blank">11558881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pharmascience.1">
<a name="Pharmascience.1"></a>pms-Hydrochlorothiazide (hydrochlorothiazide) [product monograph]. Montreal, Quebec, Canada: Pharmascience Inc; January 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28480532">
<a name="28480532"></a>Pottegård A, Hallas J, Olesen M, et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. <i>J Intern Med</i>. 2017;282(4):322-331. doi:10.1111/joim.12629<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/28480532/pubmed" id="28480532" target="_blank">28480532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31641556">
<a name="31641556"></a>Raja R, Kavita F, Amreek F, Shah A, Sayeed KA, Sehar A. Hyperuricemia associated with thiazide diuretics in hypertensive adults. <i>Cureus</i>. 2019;11(8):e5457. doi:10.7759/cureus.5457<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/31641556/pubmed" id="31641556" target="_blank">31641556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30755424">
<a name="30755424"></a>Reap LE, Rodd C, Larios J, Marshall M. Hydrochlorothiazide-induced acute generalised exanthematous pustulosis presenting with bilateral periorbital impetigo. <i>BMJ Case Rep</i>. 2019;12(2):e223528. doi:10.1136/bcr-2017-223528<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/30755424/pubmed" id="30755424" target="_blank">30755424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to the manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21655050">
<a name="21655050"></a>Roh YR, Woo SJ, Park KH. Acute-onset bilateral myopia and ciliochoroidal effusion induced by hydrochlorothiazide. <i>Korean J Ophthalmol</i>. 2011;25(3):214-217. doi:10.3341/kjo.2011.25.3.214<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/21655050/pubmed" id="21655050" target="_blank">21655050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25840695">
<a name="25840695"></a>Rosendorff C, Lackland DT, Allison M, et al; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>J Am Soc Hyperten</i>s. 2015;9(6):453-498. doi:10.1016/j.jash.2015.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/25840695/pubmed" id="25840695" target="_blank">25840695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31006143">
<a name="31006143"></a>Rosenthal A, Herrmann J. Hydrochlorothiazide-induced photosensitivity in a psoriasis patient following exposure to narrow-band ultraviolet B excimer therapy. <i>Photodermatol Photoimmunol Photomed</i>. 2019;35(5):369-371. doi:10.1111/phpp.12471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/31006143/pubmed" id="31006143" target="_blank">31006143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24243991">
<a name="24243991"></a>Roush GC, Kaur R, Ernst ME. Diuretics: a review and update. <i>J Cardiovasc Pharmacol Ther</i>. 2014;19(1):5-13. doi:10.1177/1074248413497257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/24243991/pubmed" id="24243991" target="_blank">24243991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23463403">
<a name="23463403"></a>Runyon BA; American Association for the Study of Liver Diseases. Practice guideline: management of adult patients with ascites due to cirrhosis: update 2012. http://aasld.org/sites/default/files/guideline_documents/adultascitesenhanced.pdf. Accessed May 6, 2015.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/23463403/pubmed" id="23463403" target="_blank">23463403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17296538">
<a name="17296538"></a>Ruscin JM, Page RL 2nd, Scott J. Hydrochlorothiazide-induced angioedema in a patient allergic to sulfonamide antibiotics: evidence from a case report and a review of the literature. <i>Am J Geriatr Pharmacother</i>. 2006;4(4):325-329. doi:10.1016/j.amjopharm.2006.12.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/17296538/pubmed" id="17296538" target="_blank">17296538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9793728">
<a name="9793728"></a>Santos-Victoriano M, Brouhard BH, Cunningham RJ 3rd. Renal stone disease in children. <i>Clin Pediatr (Phila)</i>. 1998;37(10):583-599.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/9793728/pubmed" id="9793728" target="_blank">9793728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25499401">
<a name="25499401"></a>Sardar GK, Eilbert WP. Severe hyponatremia associated with thiazide diuretic use. <i>J Emerg Med</i>. 2015;48(3):305-309. doi:10.1016/j.jemermed.2014.09.054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/25499401/pubmed" id="25499401" target="_blank">25499401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31403094">
<a name="31403094"></a>Schell E, Pathman J, Pescatore R, Bianchi PW. A case of thiazide-induced hypokalemic paralysis. <i>Clin Pract Cases Emerg Med</i>. 2019;3(3):211-214. doi:10.5811/cpcem.2019.3.42062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/31403094/pubmed" id="31403094" target="_blank">31403094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7176047">
<a name="7176047"></a>Scholz D, Schwille PO, Sigel A. Double-blind study with thiazide in recurrent calcium lithiasis. <i>J Urol.</i> 1982;128(5):903-907. doi:10.1016/s0022-5347(17)53269-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/7176047/pubmed" id="7176047" target="_blank">7176047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3341072">
<a name="3341072"></a>Shirey RS, Bartholomew J, Bell W, Pollack B, Kickler TS, Ness PM. Characterization of antibody and selection of alternative drug therapy in hydrochlorothiazide-induced immune hemolytic anemia. <i>Transfusion</i>. 1988;28(1):70-72. doi:10.1046/j.1537-2995.1988.28188127959.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/3341072/pubmed" id="3341072" target="_blank">3341072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21896142">
<a name="21896142"></a>Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. <i>J Clin Hypertens (Greenwich)</i>. 2011;13(9):639-643. doi:10.1111/j.1751-7176.2011.00512.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/21896142/pubmed" id="21896142" target="_blank">21896142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30425103">
<a name="30425103"></a>Sinha AD, Agarwal R. Clinical pharmacology of antihypertensive therapy for the treatment of hypertension in CKD. <i>Clin J Am Soc Nephrol</i>. 2019;14(5):757-764. doi:10.2215/CJN.04330418<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/30425103/pubmed" id="30425103" target="_blank">30425103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26987648">
<a name="26987648"></a>Sinha AD, Agarwal R. Thiazides are useful agents in CKD. <i>J Am Soc Hypertens</i>. 2016;10(4):288-9. doi:10.1016/j.jash.2016.02.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/26987648/pubmed" id="26987648" target="_blank">26987648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15242722">
<a name="15242722"></a>Slatore CG, Tilles SA. Sulfonamide hypersensitivity. <i>Immunol Allergy Clin North Am</i>. 2004;24(3):477-490.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/15242722/pubmed" id="15242722" target="_blank">15242722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23478874">
<a name="23478874"></a>Slaughter JL, Stenger MR, Reagan PB. Variation in the use of diuretic therapy for infants with bronchopulmonary dysplasia. <i>Pediatrics</i>. 2013;131(4):716-723.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/23478874/pubmed" id="23478874" target="_blank">23478874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34611920">
<a name="34611920"></a>Song G, Yoon HY, Yee J, Kim MG, Gwak HS. Antihypertensive drug use and psoriasis: a systematic review, meta- and network meta-analysis. <i>Br J Clin Pharmacol</i>. Published online October 5, 2021. doi:10.1111/bcp.15060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/34611920/pubmed" id="34611920" target="_blank">34611920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30613100">
<a name="30613100"></a>Sosenko T, Pasula S, Brahmamdam R, Girnita D. When chest pain reveals more: a case of hydrochlorothiazide-induced systemic lupus erythematosus. <i>Am J Case Rep</i>. 2019;20:26-30. doi:10.12659/AJCR.911380<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/30613100/pubmed" id="30613100" target="_blank">30613100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27389384">
<a name="27389384"></a>Spera M, Thelin C, Gandolfi A, et al. Clinical case of the month: a 35 year old woman with abdominal pain. <i>J La State Med Soc</i>. 2016;168(3):115-119.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/27389384/pubmed" id="27389384" target="_blank">27389384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1984112">
<a name="1984112"></a>Sullivan TJ. Cross-reactions among furosemide, hydrochlorothiazide, and sulfonamides. <i>JAMA</i>. 1991;265(1):120-121. doi:10.1001/jama.265.1.120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/1984112/pubmed" id="1984112" target="_blank">1984112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20964809">
<a name="20964809"></a>Taglietti F, Del Nonno F, Baiocchini A, et al. Acute hepatocellular and cholestatic injury during therapy with hydrochlorothiazide - clinicohistopathologic findings: a case report. <i>J Med Case Rep</i>. 2010;4:332. doi:10.1186/1752-1947-4-332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/20964809/pubmed" id="20964809" target="_blank">20964809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Thomopoulos.2018">
<a name="Thomopoulos.2018"></a>Thomopoulos F, Nikitakis NG, Daskalopoulos A, Piperi E, Kolomvos N, Sklavounou A. Chronic sclerosing sialadenitis of the sublingual gland: case report and literature review. <i>Stomatological Dis Sci</i>. 2018;2:8. doi:10.20517/2573-0002.2017.22</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15373844">
<a name="15373844"></a>Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. <i>Contact Dermatitis</i>. 2004;51(2):57-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/15373844/pubmed" id="15373844" target="_blank">15373844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30756041">
<a name="30756041"></a>Traversa M, Collini A, Villois P, Elia F, Verhovez A, Aprà F. When a diuretic causes pulmonary oedema. <i>Eur J Case Rep Intern Med</i>. 2018;5(6):000864. doi:10.12890/2018_000864<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/30756041/pubmed" id="30756041" target="_blank">30756041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32139213">
<a name="32139213"></a>Vadas P. Hydrochlorothiazide-induced systemic capillary leak. <i>Am J Emerg Med</i>. 2020;38(6):1299.e1-1299.e2. doi:10.1016/j.ajem.2020.02.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/32139213/pubmed" id="32139213" target="_blank">32139213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24811554">
<a name="24811554"></a>van Blijderveen JC, Straus SM, Rodenburg EM, et al. Risk of hyponatremia with diuretics: chlorthalidone versus hydrochlorothiazide. <i>Am J Med</i>. 2014;127(8):763-771. doi:10.1016/j.amjmed.2014.04.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/24811554/pubmed" id="24811554" target="_blank">24811554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16898855">
<a name="16898855"></a>van der Vorst MM, Kist JE, van der Heijden AJ, Burggraaf J. Diuretics in pediatrics: current knowledge and future prospects. <i>Paediatr Drugs</i>. 2006;8(4):245-264.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/16898855/pubmed" id="16898855" target="_blank">16898855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10477148">
<a name="10477148"></a>van Lieburg AF, Knoers NV, Monnens LA. Clinical Presentation and Follow-Up of 30 Patients With Congenital Nephrogenic Diabetes Insipidus. <i>J Am Soc Nephrol</i>. 1999;10(9):1958-1964.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/10477148/pubmed" id="10477148" target="_blank">10477148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16433212">
<a name="16433212"></a>Vereda A, Cárdaba B, Quirce S, de las Heras M, Cuesta J, Sastre J. Immunological studies in a case of hydrochlorothiazide-induced pulmonary edema. <i>J Investig Allergol Clin Immunol</i>. 2005;15(4):297-298.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/16433212/pubmed" id="16433212" target="_blank">16433212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30275849">
<a name="30275849"></a>Warrington R, Silviu-Dan F, Wong T. Drug allergy. <i>Allergy Asthma Clin Immunol</i>. 2018;14(suppl 2):60. doi:10.1186/s13223-018-0289-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/30275849/pubmed" id="30275849" target="_blank">30275849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17904464">
<a name="17904464"></a>Wermers RA, Kearns AE, Jenkins GD, Melton LJ. Incidence and clinical spectrum of thiazide-associated hypercalcemia. <i>Am J Med</i>. 2007;120(10):911.e9-911.e9.11E15. doi:10.1016/j.amjmed.2006.07.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/17904464/pubmed" id="17904464" target="_blank">17904464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i>. 2018;71(6):e13-e115. doi:10.1161/HYP.0000000000000065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22783025">
<a name="22783025"></a>Wile D. Diuretics: a review. <i>Ann Clin Biochem</i>. 2012;49(Pt 5):419-431. doi:10.1258/acb.2011.011281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/22783025/pubmed" id="22783025" target="_blank">22783025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22783025">
<a name="22783025"></a>Wilson L, Nair KV, Saseen JJ. Comparison of new-onset gout in adults prescribed chlorthalidone vs. hydrochlorothiazide for hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(12):864-868. doi:10.1111/jch.12413<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/22783025/pubmed" id="22783025" target="_blank">22783025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26395424">
<a name="26395424"></a>Zhang X, Zhao Q. Association of thiazide-type diuretics with glycemic changes in hypertensive patients: a systematic review and meta-analysis of randomized controlled clinical trials. <i>J Clin Hypertens (Greenwich)</i>. 2016;18(4):342-351. doi:10.1111/jch.12679<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/26395424/pubmed" id="26395424" target="_blank">26395424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20152742">
<a name="20152742"></a>Ziegler O, Sirveaux MA, Brunaud L, Reibel N, Quilliot D. Medical follow up after bariatric surgery: nutritional and drug issues. General recommendations for the prevention and treatment of nutritional deficiencies. <i>Diabetes Metab</i>. 2009;35(6, pt 2):544-557. doi:10.1016/S1262-3636(09)73464-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrochlorothiazide-pediatric-drug-information/abstract-text/20152742/pubmed" id="20152742" target="_blank">20152742</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13357 Version 625.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
